BusinessKey Strategies for Implementing Proteomics-Based Tests Across Disease States Highlighted in Current Opinion in BiotechnologyBy Nasdaq OMXFeb 12, 2018, 1:01 PM UTC
BusinessCell Culture Media, Sera, and Reagents Market Value to Reach US$11.3 billion by the End of 2022: Transparency Market ResearchBy Nasdaq OMXDec 20, 2017, 2:06 PM UTC
BusinessSera Prognostics to Present at the 11th Annual Canaccord Genuity Medical Technologies and Diagnostics ForumBy Nasdaq OMXNov 6, 2017, 3:00 PM UTC
BusinessSera Prognostics to Present at the Baird 2017 Global Healthcare ConferenceBy Nasdaq OMXSep 5, 2017, 2:49 PM UTC
BusinessSera Prognostics is Named a 2017 Silver Edison Award WinnerBy Nasdaq OMXApr 21, 2017, 11:00 AM UTC
BusinessSera Prognostics to Present at 35th Annual J.P. Morgan Healthcare ConferenceBy Nasdaq OMXJan 3, 2017, 3:00 PM UTC
BusinessLandmark Study Published in American Journal of Obstetrics & Gynecology Validates New Blood Test as Objective, Predictive Tool for Preterm Birth RiskBy Nasdaq OMXMar 10, 2016, 12:00 PM UTC
BusinessPositive Clinical Validation Data for PreTRM® Test Presented at the Society for Maternal-Fetal Medicine’s 36th Annual Pregnancy MeetingBy Nasdaq OMXFeb 4, 2016, 8:15 PM UTC
